Ascendis Pharma (ASND) slides 5.4% as post-FDA-approval enthusiasm fades and traders take profits

Ascendis Pharma A/S (ASND) is down 5.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The day’s drop appears more consistent with a pullback/profit-taking move after a major recent regulatory catalyst rather than a fresh negative, company-specific headline. With the broader U.S. market weaker today, ASND may also be reacting to a general risk-off tape in high-multiple biotech names.

Details:

Ascendis recently received U.S. FDA accelerated approval for YUVIWEL (navepegritide; previously developed as TransCon CNP) for increasing linear growth in children with achondroplasia aged 2 years and older with open epiphyses.

The approval was supported by Ascendis’ clinical package that included randomized, placebo-controlled trials plus open-label extension data, which likely drove a near-term re-rating and higher short-term expectations into early March.

After a big catalyst like an FDA approval, biotech stocks can retrace as investors reassess launch timing, pricing dynamics, and commercial execution risk (even without any new negative updates on the day).

U.S. equities were broadly lower today, which can amplify downside in more volatile healthcare names.

Sources:

GlobeNewswire, U.S. Food and Drug Administration, Associated Press

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ASND Hedge Fund Activity

We have seen 174 institutional investors add shares of $ASND stock to their portfolio, and 141 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,586,394 shares (-59.5%) from their portfolio in Q4 2025, for an estimated $338,282,656
AMERICAN CENTURY COMPANIES INC added 898,535 shares (+165.0%) to their portfolio in Q4 2025, for an estimated $191,603,603
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 494,995 shares (-13.3%) from their portfolio in Q4 2025, for an estimated $105,552,733
CITADEL ADVISORS LLC added 491,876 shares (+1779.6%) to their portfolio in Q4 2025, for an estimated $104,887,638
POLAR CAPITAL HOLDINGS PLC removed 487,438 shares (-56.8%) from their portfolio in Q4 2025, for an estimated $103,941,279
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 470,951 shares (+inf%) to their portfolio in Q4 2025, for an estimated $100,425,591
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 459,606 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $91,374,268

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ASND Analyst Ratings

Wall Street analysts have issued reports on $ASND in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 01/30/2026
Stifel issued a "Buy" rating on 12/11/2025
Wedbush issued a "Outperform" rating on 11/18/2025
Cantor Fitzgerald issued a "Overweight" rating on 10/13/2025

To track analyst ratings and price targets for $ASND, check out Quiver Quantitative's $ASND forecast page.

$ASND Price Targets

Multiple analysts have issued price targets for $ASND recently. We have seen 11 analysts offer price targets for $ASND in the last 6 months, with a median target of $271.0.

Here are some recent targets:

Luca Issi from RBC Capital set a target price of $275.0 on 03/03/2026
Yun Zhong from Wedbush set a target price of $273.0 on 02/12/2026
Leland Gershell from Oppenheimer set a target price of $262.0 on 02/12/2026
Tazeen Ahmad from B of A Securities set a target price of $260.0 on 01/30/2026
Eliana Merle from Barclays set a target price of $342.0 on 01/28/2026
Derek Archila from Wells Fargo set a target price of $330.0 on 01/20/2026
Yaron Weber from TD Cowen set a target price of $325.0 on 01/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.